2-氨基-4-氯苯并噻唑氢溴化物 | 27058-83-9

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氨基-4-氯苯并噻唑氢溴化物
• 中文别名: 2-氨基-4-氯苯并噻唑氢溴酸；2-氨基-4-氯苯并噻唑氢溴酸盐；2-氨基-4-氯苯并噻唑氢溴化物,97%
• 英文名称: 4-chloro-1,3-benzothiazol-2-amine hydrobromide
• 英文别名: 4-Chloro-1,3-benzothiazol-3-ium-2-amine;bromide；4-chloro-1,3-benzothiazol-3-ium-2-amine;bromide
• CAS: 27058-83-9
• 化学式: BrH*C₇H₅ClN₂S
• 分子量: 265.561
• InChiKey: DXXACNSRSDYMOR-UHFFFAOYSA-N

物化性质

• 熔点：
  240-242°C
• 稳定性/保质期：

  避免接触强氧化剂和强还原剂。

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2934200090

反应信息

• 作为反应物：
  描述：

  2-氨基-4-氯苯并噻唑氢溴化物 在 ammonium hydroxide 、 potassium hydroxide 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 2-氨基-3-氯苯硫酚
  参考文献：
  名称：

  1,4-噻嗪杂环系统的结构柔性杂环的合成及其抗菌活性

  摘要：

  在这项工作中，通过有效的合成方法，在一个步骤中就合成了4H-1,4-苯并噻嗪，该步骤涉及将取代的2-氨基苯硫醇与β-酮酸酯杂环化。合成化合物的结构由其分析和光谱数据证实。评估合成的化合物对细菌物种的抗菌活性。 Ë 。 大肠杆菌 和 蜡状芽孢杆菌 。合成的化合物显示出对微生物的显着活性，这可以与特权杂环结构支架相关。

  DOI：

  10.1007/s11164-011-0320-0
• 作为产物：
  描述：

  邻氯苯基硫脲 在 溴 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 2-氨基-4-氯苯并噻唑氢溴化物
  参考文献：
  名称：

  1,4-噻嗪杂环系统的结构柔性杂环的合成及其抗菌活性

  摘要：

  在这项工作中，通过有效的合成方法，在一个步骤中就合成了4H-1,4-苯并噻嗪，该步骤涉及将取代的2-氨基苯硫醇与β-酮酸酯杂环化。合成化合物的结构由其分析和光谱数据证实。评估合成的化合物对细菌物种的抗菌活性。 Ë 。 大肠杆菌 和 蜡状芽孢杆菌 。合成的化合物显示出对微生物的显着活性，这可以与特权杂环结构支架相关。

  DOI：

  10.1007/s11164-011-0320-0

文献信息

• Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound
  作者：Tatiana A. Giovannucci、Florian A. Salomons、Martin Haraldsson、Lotta H. M. Elfman、Malin Wickström、Patrick Young、Thomas Lundbäck、Jürgen Eirich、Mikael Altun、Rozbeh Jafari、Anna-Lena Gustavsson、John Inge Johnsen、Nico P. Dantuma

  DOI：10.1038/s41419-021-04191-9

  日期：——

  Malignant cells display an increased sensitivity towards drugs that reduce the function of the ubiquitin-proteasome system (UPS), which is the primary proteolytic system for destruction of aberrant proteins. Here, we report on the discovery of the bioactivatable compound CBK77, which causes an irreversible collapse of the UPS, accompanied by a general accumulation of ubiquitylated proteins and caspase-dependent cell death. CBK77 caused accumulation of ubiquitin-dependent, but not ubiquitin-independent, reporter substrates of the UPS, suggesting a selective effect on ubiquitin-dependent proteolysis. In a genome-wide CRISPR interference screen, we identified the redox enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) as a critical mediator of CBK77 activity, and further demonstrated its role as the compound bioactivator. Through affinity-based proteomics, we found that CBK77 covalently interacts with ubiquitin. In vitro experiments showed that CBK77-treated ubiquitin conjugates were less susceptible to disassembly by deubiquitylating enzymes. In vivo efficacy of CBK77 was validated by reduced growth of NQO1-proficient human adenocarcinoma cells in nude mice treated with CBK77. This first-in-class NQO1-activatable UPS inhibitor suggests that it may be possible to exploit the intracellular environment in malignant cells for leveraging the impact of compounds that impair the UPS.

  恶性细胞对降低泛素蛋白酶体系统（UPS）功能的药物表现出增加的敏感性，UPS是异常蛋白质降解的主要蛋白质系统。在这里，我们报告了生物活化化合物CBK77的发现，它导致UPS的不可逆性崩溃，伴随着泛素化蛋白的普遍积累和caSPase依赖的细胞死亡。CBK77导致了依赖泛素而非独立于泛素的UPS报告底物的积累，表明对依赖泛素的蛋白质降解具有选择性影响。在全基因组CRISPR干扰筛选中，我们确定了氧化还原酶NAD(P)H：喹啉醌还原酶1（NQO1）作为CBK77活性的关键介导体，并进一步证明了其作为化合物生物活化剂的作用。通过亲和力基础蛋白质组学，我们发现CBK77与泛素发生共价作用。体外实验显示，CBK77处理后的泛素结合物对去泛素化酶的解聚作用较不敏感。在NQO1-proficient人类腺癌细胞中，用CBK77处理的裸鼠显示了CBK77的体内有效性。这种首创的NQO1活化的UPS抑制剂表明，可能可以利用恶性细胞内部环境来增强影响破坏UPS的化合物的作用。

• Synthesis, cytotoxic evaluation, and in silico studies of substituted N-alkylbromo-benzothiazoles
  作者：Rupinder Kaur Gill、Gagandeep Singh、Anuradha Sharma、P. M. S. Bedi、A. K. Saxena

  DOI：10.1007/s00044-012-0424-0

  日期：2013.9

  In efforts to develop a new class of anticancer agents with improved efficacy and selective action, a series of N-alkylbromo-benzothiazoles were synthesized and evaluated for in vitro cytotoxic activity against various human cancer cell lines such as lung (A-549), prostate (PC-3), leukemia (THP-1), and colon (Caco-2). They were found to be highly active against prostate (PC-3) and leukemia (THP-1) cancer cells, moderately active against colon (Caco-2) cancer cells and less active against lung (A-549) cancer cells. Of the 12 compounds, two (11d, 11j) exhibit IC50 values of a parts per thousand currency sign 1 mu M against leukemia (THP-1) cancer cell lines. Compound 11l showed significant cytotoxic activity against the PC-3 (IC50 = 0.6 mu M), THP-1 (IC50 = 3 mu M) and Caco-2 cell lines (IC50 = 9.9 mu M), respectively. Docking study of the synthesized ligand was done on epidermal growth factor receptor using ArgusLab flexible docking, to determine their observed activity. Further QSAR investigations with stepwise multiple linear regression analysis were applied to find correlation between various physicochemical parameters and anticancer activity. The QSAR results showed that anticancer activity could be modeled with descriptors. The predictive ability of models was cross-validated by observation of the low residual activity values and adjusted coefficient of variation () obtained by leave-one-out technique.